title: Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy.
abstract: BACKGROUND
  To determine the impact of various preoperative serum prostate specific antigen (PSA) levels in the range from 0.1 to 10 ng/ml on pathological stage and disease-free survival after radical prostatectomy.
  
  
  METHODS
  We selected a cohort of 585 patients who underwent radical prostatectomy between 1991-1996 for clinically localized prostate cancer and presented with preoperative serum PSA levels from 0.1 to 10 ng/ml.
  
  
  RESULTS
  Pathological organ-confined disease was present in 57.6% of patients. The rate of organ-confined disease decreased from an average of 85% for patients with a PSA value < 2 ng/ml, to 46.8% for patients with a PSA value > 7 ng/ml. We found statistically significant correlations between preoperative serum PSA level and overall pathological stage (P = 0.001), pathologically organ-confined disease (P = 0.001), margin positive rates (P = 0.001), extra prostatic extension (P = 0.001), and seminal vesicle invasion (P = 0.001). The overall disease-free survival rate was 87%, with a median follow up of 42.4 months. Disease free survival was significantly better for patients with PSA up to 4 ng/ml (P = 0.005).
  
  
  CONCLUSIONS
  Our data suggests that PSA detection programs should strive to detect prostate cancer in men before the PSA level rises above 7 ng/ml. In addition, since patients with a PSA level < 4 ng/ml had better disease-free survival rates than those with a PSA level between 4.1-10 ng/ml, eliminating an arbitrary cutoff of 4 ng/ml, may lead to improved disease-free survival.
authors.affiliation: Department of Urology, Wayne State University and School of Medicine, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.
authors.forename: B
authors.initials: B
authors.lastname: Shekarriz
authors.forename: J
authors.initials: J
authors.lastname: Upadhyay
authors.forename: F J
authors.initials: FJ
authors.lastname: Bianco
authors.forename: M V
authors.initials: MV
authors.lastname: Tefilli
authors.forename: R
authors.initials: R
authors.lastname: Tiguert
authors.forename: E L
authors.initials: EL
authors.lastname: Gheiler
authors.forename: D J
authors.initials: DJ
authors.lastname: Grignon
authors.forename: J E
authors.initials: JE
authors.lastname: Pontes
authors.forename: D P
authors.initials: DP
authors.lastname: Wood
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011300:Preoperative Care; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D016019:Survival Analysis
chemical_list: D017430:Prostate-Specific Antigen